SPC
MBRX icon

Sigma Planning Corp’s Moleculin Biotech MBRX Stock Holding History

Sigma Planning Corp’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-32
Closed -$10.3K – 1238
2023
Q4 		$10.3K Sell
32
-13
-29% -$2.7K ﹤0.01% 838
2023
Q3 		$7.27K Hold
45
– – ﹤0.01% 1190
2023
Q2 		$9.84K Sell
45
-108
-71% -$28.5K ﹤0.01% 1191
2023
Q1 		$55.2K Hold
153
– – ﹤0.01% 1263
2022
Q4 		$61K Hold
153
– – ﹤0.01% 1223
2022
Q3 		$61K Hold
153
– – ﹤0.01% 1211
2022
Q2 		$83K Hold
153
– – ﹤0.01% 1223
2022
Q1 		$102K Buy
153
+38
+33% +$21.8K ﹤0.01% 1305
2021
Q4 		$80K Buy
+115
New +$102K ﹤0.01% 1336

Other funds holding MBRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AWM
Atticus Wealth Management Palm Beach Gardens, Florida $420M AUM 23.31% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FIM
FWL Investment Management Dallas, Texas $456M AUM 60.63% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return

Sigma Planning Corp's MBRX Position: Q1 2024 in Review

Sigma Planning Corp sold out of Moleculin Biotech (MBRX) in Q1 2024, closing a stake of 32 shares — an estimated $10.3K sold.

Sigma Planning Corp first reported a position in MBRX in Q4 2021 and held it in 9 quarters. The position peaked at $102K in Q1 2022. 15 funds tracked by Wall St. Rank hold MBRX as of Q1 2024.

  • Sigma Planning Corp reported no remaining Moleculin Biotech position as of Q1 2024 after selling out during the quarter.
  • Sigma Planning Corp sold 32 Moleculin Biotech shares in Q1 2024, an estimated $10.3K.
  • Sigma Planning Corp first reported a position in Moleculin Biotech in Q4 2021 and held it in 9 quarters.
  • Sigma Planning Corp's Moleculin Biotech position peaked at $102K in Q1 2022.
  • 15 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2024.

Based on Sigma Planning Corp's 13F filing for Q1 2024, filed 2 May 2024.